Related Experiment Video

Updated: Jun 20, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Antitumor activity of a novel antisense oligonucleotide against Akt1

Heejeong Yoon1, Deog Joong Kim, Eun Hyun Ahn

  • 1Rexahn Pharmaceuticals, Inc., 20271 Goldenrod Lane, Germantown, Maryland 20876, USA.

Journal of Cellular Biochemistry
|August 21, 2009
PubMed

Insights

An Akt1 antisense oligonucleotide (Akt1 AO) effectively inhibited cancer cell growth and tumor development in preclinical models. This agent shows promise as a novel therapeutic for various cancers, alone or combined with existing treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • The AKT pathway is a critical regulator of cell signaling implicated in numerous cancers.
  • Dysregulation of the AKT pathway contributes to cancer development and progression.
  • Targeting the AKT pathway presents a significant opportunity for novel cancer therapeutics.

Purpose of the Study:

  • To evaluate the efficacy of an Akt1 antisense oligonucleotide (Akt1 AO) as a potential cancer therapeutic.
  • To investigate the effects of Akt1 AO on cancer cell growth and tumor development in preclinical models.

Main Methods:

  • Treatment of various human cancer cell lines with Akt1 AO to assess gene and protein expression and cellular growth inhibition.
  • Combination therapy studies involving Akt1 AO and cytotoxic drugs in Caki-1 cells.
  • In vivo efficacy studies using xenograft nude mouse models implanted with human glioblastoma (U251) and pancreatic cancer (MIA-Luc) cells.

Main Results:

  • Akt1 AO significantly downregulated AKT1 mRNA and protein expression in cancer cells.
  • Akt1 AO demonstrated potent cellular growth inhibition at nanomolar concentrations.
  • Combined treatment with Akt1 AO and cytotoxic drugs showed additive growth inhibition.
  • In vivo, Akt1 AO significantly inhibited tumor growth in both glioblastoma and pancreatic cancer xenograft models.
  • Tumor growth and luciferase signals were markedly reduced or abolished in MIA-Luc tumor-bearing mice.

Conclusions:

  • Akt1 AO effectively inhibits cancer cell growth and tumor progression through downregulation of AKT1.
  • Akt1 AO exhibits significant therapeutic potential as a monotherapy or in combination with other anticancer agents.
  • Further clinical investigation of Akt1 AO is warranted for cancer treatment development.

More Related Videos

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...